We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Aimmune (AIMT) This Earnings Season?
Read MoreHide Full Article
We expect investors to focus on Aimmune Therapeutics, Inc.’s updates related to the commercialization plan for its newly approved peanut allergy drug, Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp], during fourth-quarter 2019 earnings call.
The company’s earnings record has been dismal so far with negative surprises in three of the last four quarters while a beat in one. The four-quarter miss is 4.06%, on average. In the last reported quarter, Aimmune came up with a negative surprise of 1.98%.
Shares of Aimmune have rallied 20.9% in the past year against the industry’s decrease of 3%.
Let’s see how things have shaped up prior to this announcement.
Factors to Watch
In January 2020, the FDA approved Aimmune’s lead pipeline candidate AR101 for the treatment of patients with peanut allergy under the trade name, Palforzia. The drug is the first FDA-approved product in the company’s portfolio. We expect Aimmune to provide an update on its commercialization plan for the launch of the drug during fourth-quarter earnings call.
Following this nod, Palforzia becomes the first approved therapy to address the given patient population.
Palforzia, an oral immunotherapy is designed to reduce the incidence and severity of allergic reactions including anaphylaxis, which may occur due to accidental exposure to peanut. The drug is to be administered in conjunction with peanut-avoidant diet and only in patients with confirmed diagnosis of peanut allergy.
However, the prescribing information on Palforzia comes with a boxed warning.
Regulatory activities regarding the introduction of Palforzia and the ongoing clinical studies are likely to have escalated the operating expense in the fourth quarter. However, completion of certain clinical studies on Palforzia might have partially offset this rise in expenses.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Aimmune this season. The right combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of a positive surprise. But that is not the case here.You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Aimmune has an Earnings ESP of -0.96%.
Zacks Rank: Aimmune carries a Zacks Rank #3, which increases the predictive power of ESP. However, its negative ESP leaves surprise prediction inconclusive.
Here are a few healthcare stocks worth considering with the right mix of elements to beat estimates this time around.
Clovis Oncology, Inc. has an Earnings ESP of +0.81% and a Zacks Rank #2. The company is scheduled to release earnings results on Feb 24.
Sage Therapeutics, Inc. (SAGE - Free Report) has an Earnings ESP of +2.74% and a Zacks Rank of 3. The company is scheduled to release earnings results on Feb 27.
Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
Image: Bigstock
What's in Store for Aimmune (AIMT) This Earnings Season?
We expect investors to focus on Aimmune Therapeutics, Inc.’s updates related to the commercialization plan for its newly approved peanut allergy drug, Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp], during fourth-quarter 2019 earnings call.
The company’s earnings record has been dismal so far with negative surprises in three of the last four quarters while a beat in one. The four-quarter miss is 4.06%, on average. In the last reported quarter, Aimmune came up with a negative surprise of 1.98%.
Shares of Aimmune have rallied 20.9% in the past year against the industry’s decrease of 3%.
Let’s see how things have shaped up prior to this announcement.
Factors to Watch
In January 2020, the FDA approved Aimmune’s lead pipeline candidate AR101 for the treatment of patients with peanut allergy under the trade name, Palforzia. The drug is the first FDA-approved product in the company’s portfolio. We expect Aimmune to provide an update on its commercialization plan for the launch of the drug during fourth-quarter earnings call.
Following this nod, Palforzia becomes the first approved therapy to address the given patient population.
Palforzia, an oral immunotherapy is designed to reduce the incidence and severity of allergic reactions including anaphylaxis, which may occur due to accidental exposure to peanut. The drug is to be administered in conjunction with peanut-avoidant diet and only in patients with confirmed diagnosis of peanut allergy.
However, the prescribing information on Palforzia comes with a boxed warning.
Regulatory activities regarding the introduction of Palforzia and the ongoing clinical studies are likely to have escalated the operating expense in the fourth quarter. However, completion of certain clinical studies on Palforzia might have partially offset this rise in expenses.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Aimmune this season. The right combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of a positive surprise. But that is not the case here.You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Aimmune has an Earnings ESP of -0.96%.
Zacks Rank: Aimmune carries a Zacks Rank #3, which increases the predictive power of ESP. However, its negative ESP leaves surprise prediction inconclusive.
Aimmune Therapeutics, Inc. Price and EPS Surprise
Aimmune Therapeutics, Inc. price-eps-surprise | Aimmune Therapeutics, Inc. Quote
Stocks That Warrant a Look
Here are a few healthcare stocks worth considering with the right mix of elements to beat estimates this time around.
Clovis Oncology, Inc. has an Earnings ESP of +0.81% and a Zacks Rank #2. The company is scheduled to release earnings results on Feb 24.
Sage Therapeutics, Inc. (SAGE - Free Report) has an Earnings ESP of +2.74% and a Zacks Rank of 3. The company is scheduled to release earnings results on Feb 27.
Immunomedics, Inc. has an Earnings ESP of +3.37% and a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
See 5 Stocks Set to Double>>